Repository logo
 

Overexpression of Igf2-derived Mir483 inhibits Igf1 expression and leads to developmental growth restriction and metabolic dysfunction in mice.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Change log

Abstract

Mir483 is a conserved and highly expressed microRNA in placental mammals, embedded within the Igf2 gene. Its expression is dysregulated in a number of human diseases, including metabolic disorders and certain cancers. Here, we investigate the developmental regulation and function of Mir483 in vivo. We find that Mir483 expression is dependent on Igf2 transcription and the regulation of the Igf2/H19 imprinting control region. Transgenic Mir483 overexpression in utero causes fetal, but not placental, growth restriction through insulin-like growth factor 1 (IGF1) and IGF2 and also causes cardiovascular defects leading to fetal death. Overexpression of Mir483 post-natally results in growth stunting through IGF1 repression, increased hepatic lipid production, and excessive adiposity. IGF1 infusion rescues the post-natal growth restriction. Our findings provide insights into the function of Mir483 as a growth suppressor and metabolic regulator and suggest that it evolved within the INS-IGF2-H19 transcriptional region to limit excessive tissue growth through repression of IGF signaling.

Description

Journal Title

Cell Rep

Conference Name

Journal ISSN

2639-1856
2211-1247

Volume Title

Publisher

Elsevier

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Medical Research Council (MR/J001562/1)
Medical Research Council (MC_PC_12012)
Medical Research Council (MR/M009041/1)
MRC (MC_UU_00014/4)
Cancer Research UK (12014)
Biotechnology and Biological Sciences Research Council (BB/D007909/1)
Biotechnology and Biological Sciences Research Council (BB/M001865/1)
This work was supported by the Medical Research Council (MR/J001562/1 to M.C.; MRC_MC_UU_12014/4 to M.C. and S.E.O.; MRC_MC_UU_12012/5 to the MRC Metabolic Diseases Unit; MR/M009041/1 – “Enhancing UK Clinical Research” grant supporting the TQ-XS work); the Biotechnology and Biological Sciences Research Council (BBSRC BB/F014279/2 to A.E.W. and M.B.) and the Cancer Research UK (CRUK Institute award A29252 to M.B.); N.C. was funded by the Frank Edward Elmore Fund, the Association of Physicians of Great Britain & Ireland and the Anatomical Society; Y.S. was funded by post-doctoral fellowships from the Uehara Memorial Foundation and the Japan Society for the Promotion of Science; D.C. was funded by the Erasmus placement programme; K.B.Q. was funded by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES, Brazil.